CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 656 enrolled
Drug / intervention
Combination Tablet of Treximet (sumatriptan/naproxen sodium)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00488514
NCT00488514Phase 3Completed
CompareCT.gov

Study TXA107977, a Long-Term Safety Study of a Combination Product Containing Sumatriptan Succinate and Naproxen Sodium for the Treatment of Migraine in Adolescents

GlaxoSmithKline·interventional·Posted Jun 20, 2007·Updated May 18, 2017

In Brief

A Phase 3 clinical trial evaluating Combination Tablet of Treximet (sumatriptan/naproxen sodium) for Migraine Disorders. Completed, enrolled 656 participants across 77 sites.

Detailed Summary

This study was designed to determine long-term safety of TREXIMET (sumatriptan/naproxen sodium) in adolescents for the acute treatment of migraine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine Disorders
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 20, 2007
Enrollment StartJul 13, 2007
Primary CompletionAug 1, 2009
Study CompletionAug 20, 2009
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 19.0 years ago

Interventions

Combination Tablet of Treximet (sumatriptan/naproxen sodium)drug

Combination Tablet of Treximet(sumatriptan/naproxen sodium)